You have full text access to this OnlineOpen article

Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system

  1. Ryutaro Asano1,
  2. Makoto Nakayama1,
  3. Hiroko Kawaguchi1,
  4. Tsuguo Kubota1,
  5. Takeshi Nakanishi1,
  6. Mitsuo Umetsu1,
  7. Hiroki Hayashi2,
  8. Yu Katayose2,
  9. Michiaki Unno2,
  10. Toshio Kudo3,
  11. Izumi Kumagai1

Article first published online: 6 DEC 2011

DOI: 10.1111/j.1742-4658.2011.08417.x

Issue

FEBS Journal

FEBS Journal

Volume 279, Issue 2, pages 223–233, January 2012

Additional Information

How to Cite

Asano, R., Nakayama, M., Kawaguchi, H., Kubota, T., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T. and Kumagai, I. (2012), Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system. FEBS Journal, 279: 223–233. doi: 10.1111/j.1742-4658.2011.08417.x

Author Information

  1. 1

     Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan

  2. 2

     Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan

  3. 3

     Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan

*Izumi Kumagai, Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Aoba 6-6-11-606, Aramaki, Aoba-ku, Sendai 980-8579, Japan Fax: +81 22 795 6164 Tel: +81 22 795 7274 E-mail: kmiz@kuma.che.tohoku.ac.jp

Publication History

  1. Issue published online: 3 JAN 2012
  2. Article first published online: 6 DEC 2011
  3. Accepted manuscript online: 10 NOV 2011 12:07PM EST
  4. (Received 10 February 2011, revised 4 November 2011, accepted 7 November 2011)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (601K)

References

  • 1
    Cao Y & Lam L (2003) Bispecific antibody conjugates in therapeutics. Adv Drug Del Rev 55, 171–197.
  • 2
    Kufer P, Lutterbuse R & Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22, 238–244.
  • 3
    Raso V & Griffin T (1981) Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res 41, 2073–2078.
  • 4
    Suresh MR, Cuello AC & Milstein C (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 121, 210–228.
  • 5
    Kriangkum J, Xu B, Nagata LP, Fulton RE & Suresh MR (2001) Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 18, 31–40.
  • 6
    Perisic O, Webb PA, Holliger P, Winter G & Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217–1226.
  • 7
    Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M & Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 2562–2568.
  • 8
    Gao Y, Xiong D, Yang M, Liu H, Peng H, Shao X, Xu Y, Xu C, Fan D, Qin L et al. (2004) Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 18, 513–520.
  • 9
    Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, Knackmuss S & Little M (2002) Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin’s lymphoma. J Immunol 169, 137–144.
  • 10
    Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, Fan D, Yang M, Han J, Xie Y et al. (2002) Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett 177, 29–39.
  • 11
    Asano R, Takemura S, Tsumoto K, Sakurai N, Teramae A, Ebara S, Katayose Y, Shinoda M, Suzuki M, Imai K et al. (2000) Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system. J Biochem (Tokyo) 127, 673–679.
  • 12
    Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K & Kumagai I (2002) Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem (Tokyo) 132, 903–909.
  • 13
    Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 4036–4042.
  • 14
    Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597–603.
  • 15
    Foote J & Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224, 487–499.
  • 16
    Vargas-Madrazo E & Paz-Garcia E (2003) An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. J Mol Recognit 16, 113–120.
    Direct Link:
  • 17
    Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P & Zeillinger R (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17, 613–619.
  • 18
    Ferrini S, Cambiaggi A, Sforzini S, Marciano S, Canevari S, Mezzanzanica D, Colnaghi MI, Grossi CE & Moretta L (1993) Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation. Int J Cancer 55, 931–937.
    Direct Link:
  • 19
    Pfosser A, Brandl M, Salih H, Grosse-Hovest L & Jung G (1999) Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int J Cancer 80, 612–616.
    Direct Link:
  • 20
    Nagorsen D & Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317, 1255–1260.
  • 21
    Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T & Kumagai I (1998) Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent – application to a human single-chain Fv fragment. J Immunol Methods 219, 119–129.
  • 22
    Jones PT, Dear PH, Foote J, Neuberger MS & Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525.
  • 23
    Riechmann L, Clark M, Waldmann H & Winter G (1988) Reshaping human antibodies for therapy. Nature 332, 323–327.
  • 24
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP & Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86, 10029–10033.
  • 25
    Co MS, Deschamps M, Whitley RJ & Queen C (1991) Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A 88, 2869–2873.
  • 26
    Ohtomo T, Tsuchiya M, Sato K, Shimizu K, Moriuchi S, Miyao Y, Akimoto T, Akamatsu K, Hayakawa T & Ohsugi Y (1995) Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol Immunol 32, 407–416.
  • 27
    Nakanishi T, Tsumoto K, Yokota A, Kondo H & Kumagai I (2008) Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10. Protein Sci 17, 261–270.
    Direct Link:
  • 28
    Lu D, Jimenez X, Witte L & Zhu Z (2004) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 318, 507–513.
  • 29
    Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B & Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 ×  CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098–2103.
  • 30
    Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R et al. (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130, 218–228.
    Direct Link:
  • 31
    Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F et al. (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31, 871–884.
  • 32
    Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A et al. (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 33, 599–608.
  • 33
    Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ et al. (2004) A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 125, 167–179.
    Direct Link:
  • 34
    Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2010) Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 277, 477–487.
    Direct Link:
  • 35
    Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 31, 752–761.
  • 36
    Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M et al. (2010) Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 285, 20844–20849.
  • 37
    Ono K, Ohtomo T, Yoshida K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M & Tsuchiya M (1999) The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol 36, 387–395.
  • 38
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T & Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53, 851–856.
  • 39
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T & Bendig MM (1994) Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immunol 31, 371–381.
  • 40
    Wang X & Stollar BD (1999) Immunoglobulin VH gene expression in human aging. Clin Immunol 93, 132–142.
  • 41
    Ramsland PA, Brock CR, Moses J, Robinson BG, Edmundson AB & Raison RL (1999) Structural aspects of human IgM antibodies expressed in chronic B lymphocytic leukemia. Immunotechnology 4, 217–229.
  • 42
    Yokota A, Tsumoto K, Shiroishi M, Kondo H & Kumagai I (2003) The role of hydrogen bonding via interfacial water molecules in antigen-antibody complexation. The HyHEL-10-HEL interaction. J Biol Chem 278, 5410–5418.
  • 43
    Sondermann P & Jacob U (1999) Human Fcgamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem 380, 717–721.
  • 44
    Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M & Kumagai I (2011) Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem 286, 1812–1818.
  • 45
    Kabat EA, Wu TT, Perry HM, Gottesman KS & Foeller C (1991) Sequences of Proteins of Immunological Interest, 5th edn. National Institutes of Health, Bethesda, MD.
View Full Article (HTML) Get PDF (601K)